Ascendis Pharma Past Earnings Performance
Past criteria checks 0/6
Ascendis Pharma's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 72.7% per year.
Key information
-21.7%
Earnings growth rate
-17.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 72.7% |
Return on equity | n/a |
Net Margin | -152.4% |
Next Earnings Update | 03 Sep 2024 |
Recent past performance updates
Recent updates
Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk
Jul 20Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S
Apr 05Ascendis Pharma's Ambitious Vision 2030
Jan 11What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You
Dec 21Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?
Nov 10Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing
Oct 05Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?
Jun 27Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week
May 05Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?
Feb 18Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?
Sep 24Ascendis Pharma: TransCon CNP Data Coming Q4
Sep 15Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH
Aug 31Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa
Aug 11Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect
Aug 03Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money
Jun 10Ascendis Pharma: Biotech Bear Provides Attractive Entry Point
May 09Ascendis: Institutional Buying Activity Now Seen As Good Value By Market-Makers
Apr 29Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 51% Above Its Share Price
Feb 24Is Ascendis Pharma (NASDAQ:ASND) In A Good Position To Invest In Growth?
Jan 07Ascendis: Danish Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Dec 30Revenue & Expenses Breakdown
How Ascendis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 329 | -502 | 265 | 378 |
31 Dec 23 | 267 | -481 | 264 | 413 |
30 Sep 23 | 152 | -602 | 257 | 431 |
30 Jun 23 | 119 | -609 | 254 | 417 |
31 Mar 23 | 78 | -569 | 240 | 403 |
31 Dec 22 | 51 | -583 | 221 | 380 |
30 Sep 22 | 33 | -482 | 213 | 337 |
30 Jun 22 | 19 | -393 | 192 | 298 |
31 Mar 22 | 14 | -446 | 170 | 291 |
31 Dec 21 | 8 | -384 | 160 | 296 |
30 Sep 21 | 3 | -416 | 132 | 491 |
30 Jun 21 | 5 | -458 | 111 | 432 |
31 Mar 21 | 5 | -418 | 96 | 349 |
31 Dec 20 | 7 | -419 | 77 | 261 |
30 Sep 20 | 9 | -360 | 73 | 50 |
30 Jun 20 | 8 | -264 | 66 | 192 |
31 Mar 20 | 10 | -228 | 56 | 140 |
31 Dec 19 | 13 | -218 | 48 | 192 |
30 Sep 19 | 21 | -170 | 40 | 179 |
30 Jun 19 | 19 | -178 | 37 | 70 |
31 Mar 19 | 16 | -142 | 31 | 161 |
31 Dec 18 | 11 | -130 | 25 | 140 |
30 Sep 18 | 0 | -132 | 21 | 130 |
30 Jun 18 | 1 | -132 | 17 | 128 |
31 Mar 18 | 1 | -140 | 15 | 110 |
31 Dec 17 | 2 | -124 | 13 | 100 |
30 Sep 17 | 2 | -106 | 13 | 92 |
30 Jun 17 | 3 | -91 | 12 | 79 |
31 Mar 17 | 4 | -73 | 12 | 70 |
31 Dec 16 | 5 | -69 | 12 | 66 |
30 Sep 16 | 6 | -64 | 12 | 59 |
30 Jun 16 | 6 | -53 | 10 | 50 |
31 Mar 16 | 7 | -55 | 10 | 49 |
31 Dec 15 | 8 | -33 | 9 | 41 |
30 Sep 15 | 9 | -26 | 8 | 36 |
30 Jun 15 | 10 | -21 | 8 | 31 |
31 Mar 15 | 12 | -8 | 8 | 23 |
31 Dec 14 | 14 | -10 | 6 | 20 |
30 Sep 14 | 17 | -2 | 4 | 15 |
30 Jun 14 | 20 | 0 | 3 | 15 |
31 Mar 14 | 20 | 3 | 3 | 13 |
31 Dec 13 | 20 | 4 | 2 | 13 |
Quality Earnings: ASND is currently unprofitable.
Growing Profit Margin: ASND is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ASND is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.
Accelerating Growth: Unable to compare ASND's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASND is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: ASND's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.